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BACKGROUND: Blood transfusion is a life-saving procedure; 
millions of lives are saved each year. However, blood transfusions 
are associated with certain risks that can lead to adverse 
consequences. This study aimed to survey the prevalence and trend 
of hepatitis B virus (HBV), hepatitis C virus (HCV), and Human 
immunodeficiency virus (HIV) among blood donors of Fars 
province, Iran (2006-2018).  
METHODS: This retrospective cross-sectional study was 
conducted by reviewing the records of the blood transfusion 
organization of Fars province. A total of 1952478 blood units were 
screened for transfusion-transmitted infections (TTIs). Then, data 
were entered into SPSS software (Negare. version 25). Chi-square 
test was used to compare the sof TTIs among blood donors. Chi-
square test for trend was used to analyze the variations in trends of 
TTIs during this period. Finally, p-values less than 0.05 were 
considered statistically significant. GraphPad Prism software was 
used for the depiction of the graphs. 
RESULTS: Among the 1952478 blood donations within the 13-
years, 4479(0.229 %) of donors were HBsAg, HCV Ab, and HIV 
Ag-Ab positive. The seroprevalence of HBV, HCV, and HIV was 
2684(0.137%), 1703(0.087 %), and 92(0.0047%), respectively.  
CONCLUSION: The current study showed that the overall 
prevalence of TTIs among blood donors was low and had a 
descending trend over the years of study. 





Blood transfusion is a life-saving procedure, and millions of lives are 
saved each year. However, blood transfusions are associated with 
certain risks that can lead to adverse consequences. It may cause 
acute or delayed complications and carries the risk of the 
transmission of infections that might be fatal rather than that of 
saving life (1). The discovery of transfusion-transmissible infections 
(TTIs) has heralded a new era in blood transfusion medicine 
worldwide with the emphasis on two fundamental
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objectives: safety, and protection of human life (2). 
TTIs; namely, hepatitis B virus (HBV), hepatitis C 
virus (HCV), Human Immunodeficiency Virus 
(HIV), and syphilis are major challenges to blood 
transfusion services. These viruses create a big 
challenge for blood safety because of their 
prolonged viraemia, carrier, latent state and chronic 
state, and life-threatening complications.  
The World Health Organization (WHO) 
reported that 37.9 million [32.7 million-44.0 
million] people globally were living with HIV at 
the end of 2018. Also, an estimated 0.8% [0.6-
0.9%] of adults aged 15-49 years are living with 
HIV worldwide (3). In Iran, the prevalence of HIV 
and other blood-borne viral infections is relatively 
low in the general population (4). The HIV 
prevalence in different subgroups varied from 
0.00% in the general population to 17.25% in 
intravenous drug abusers (5). HBV is extremely 
contagious and relatively easy to transmit from 
infected individuals to others through some ways 
like birth, unprotected sex, blood transfusion, and 
also sharing needles. In various areas of the world, 
the incidence of HBV infection varied from 0.1 to 
20%(6). Iran was categorized among countries with 
low-intermediate HBV prevalence, where its 
prevalence was reported between 2-4% in the 
general population (7). Also, the worldwide 
prevalence of HCV infection among HCV blood 
donors varies from 0.4% to 19.2% (8). 
Because of the risk of infected donations 
despite screening tests, HBV, HCV, and HIV are 
considered as one of the major challenges of blood 
safety globally. Thus, it is necessary to survey the 
prevalence and trend of TTIs in blood donors to 
estimate the infectious risk through blood 
transfusion and the effectiveness of safety 
measures that were taken in Fars BTO. Thus, this 
study aimed to survey the seroprevalence and trend 
of HBV, HCV, and HIV infections among blood 
donors of Fars province, Iran, between 2006 to 
2018. 
 
METHODS AND MATERIALS 
 
This retrospective, cross-sectional study on the 
TTIs was conducted at Blood Transfusion 
Organization of Fars, Iran. Fars province is one of 
the thirty-one provinces of Iran which is located in 
the south of the country and has an area of 122,400 
km².  In 2011, this province had a population of 
about 4.6 million people (9). A total of 1,952,478 
blood donations carried out in blood centers of Fars 
province between 1 January 2006 and 31 
December 2018 were included in this study. The 
identical standard measures were used for blood 
donor recruitment, selection, deferral and 
laboratory tests in all centers of Blood Transfusion. 
Blood donors were volunteers, and their eligibility 
for donation was determined by the history and 
physical and hematological examinations before 
blood donation. For screening infectious diseases, 
the samples were collected in pilot test tubes at the 
time of blood donation. They were examined in the 
screening laboratory of the Shiraz Blood 
Transfusion Organization. 
HBsAg, HCV-Ab, and HIV Ag-Ab positivity: 
Testing for HBsAg, anti-HCV, and anti-HIV was 
performed using the kits listed in Table 1 according 
to the manufacturer's instructions and all the 
standard protocols were followed. All initial 
positive results were checked by performing a 
double check test using the same assay on the same 
pilot. Confirmatory or supplemental tests such as 
western blot for HIV, neutralization for HBV and 
confirmatory recombinant immunoblot assay 
(RIBA) for HCV were performed on the blood 
samples of blood units (Tables 2, 3). 
Then, the records including data on the 
donation type and date, demographic 
characteristics such as age, gender, marital status 
and results of serologic tests were extracted from 
statistical software of Blood Transfusion 
Organization (Negara). It should be noted that the 
donors were classified into three groups: "First-
time donor" was referred to a person who had not a 
history of blood donation. "Regular donor" referred 
to anyone who donated blood at least twice a year, 
and "Repeatdonor" was a person who had a history 
of previous donations, but the interval between two 
donations was longer than a year.  
Statistical analysis: Data were entered into SPSS 
software (Negare. version 25). All data were 
prepared as frequencies and percentages for basic 
descriptive statistics. The yearly seroprevalence of 
TTIs was provided for all the study populations and 
different socio-demographic characteristics. Chi-
square test was used to compare the sof TTIs 
among blood donors. Chi-square test for trend was 
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used to analyze the variations in trends of TTIs 
during this period. Finally, p-values less than 0.05 
was considered statistically significant. GraphPad 
Prism software was used for the depiction of the 
graphs. 
Ethical considerations  
This study was approved by the ethics committee 
of Gerash University of Medical Sciences, Gerash, 





Characteristics of Donors: Throughout the study, 
1952478 donations were collected between 1 
January 2006 and 31 December 2018. The number 
of donations progressively increased from 137458 
in 2006 to 158028 in 2018. Among the blood 
donors, 1,853,118(94.9%) and 99,360(5.08%) were 
males and females, respectively. 
Findings of HBsAg, HCV-Ab, and HIV Ag-Ab 
positivity: The results of serological screening tests 
for HBV, HCV and HIV infections showed that the 
prevalence was 2684(0.137 %) for HBsAg, 
1703(0.087 %) for anti-HCV, and 92(0.0047%) for 
HIV. Briefly, HBS had the highest prevalence, 
while HIV had the lowest one. The distribution of 
seroprevalences of HBsAg, anti-HCV, and anti-
HIV 1/2 antibodies according to the years is shown 
in Table 1 and Figures 1,2 and 3.  Also, the 
demographic characteristics of the viral infectious 
positive blood donors are shown in Table 1. 
The results of blood donation showed that 
although the blood donation rate increased during 
this period, the prevalence of HBs Ag among blood 
donors during this period had a downward trend. 
This decline was almost the same in initial, double 
checks and confirmatory tests. Also, the highest 
prevalence of HBs Ag was observed in the range of 
31 to 50 years old. Regarding HCV, this trend is 
also descending and the highest levels of infection 
were reported in the people aged 26 to 40 years. 
The trend of HIV infection frequency was 
relatively fluctuating, as it had an increasing 
pattern from 2006 to 2009, but showed a 
descending trend after 2009. Also, donors between 
26 to 35 years old had the highest levels of HIV 
infection. The trend of prevalence rates of HBS, 
HCV, and HIV from 2006 to 2018 is shown in 
Figurs1-3. Considering the related risk factors such 
as gender, marital status, and type of donors, it was 
revealed that the prevalence of these infections 
among males was higher than among females, and 
it was higher among married people compared to 
single ones. Finally, the prevalence among the first 
time donors was significantly higher than than the 
ones among regular and repeat donors (Table 1). 
 
Table 1: Yearly seroprevalence of confirmed HBV, HCV, and HIV infections according to socio-demographic 











Male No (%) First time donor 
No (%) 
repeat donor 
Male  )%( No 
Regular donor 
( No) (%) ale 
 HBSAg 2684 180 (6.7 %) 2504(93.3%) 2341(87.22%) 164 (6.11%) 179 (6.66 %) 
HCV 1703 40 (2.35 %) 1663(97.71%) 1466(86.08%) 132 (7.75 %) 105(6.17 %)
  
HIV 92 10 (10.87 
%) 
82 (89.13 %) 70 (76.09 %) 17 (18.48 %) 5 (5.43 %) 






Age groups  








HBSAg 2684 (0.137 
%) 
123 304 311 318 322 340 335 273 131 36 
HCV 1703 (0.087 
%) 
32 147 351 366 258 165 125 89 40 4 
HIV 92 
(0.0047%) 
4 11 19 26 12 9 4 0 1 0 
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Table 2: The kits used in donor screening, 2006-2018. 
 
 
HIV Ag-Abs Screening test kit Anti-HCV Screening test 
 




HIV Ag-Ab  Ultra Biorad 
 
Monolisa Anti-HCV Plus v3 
Biorad 
 
EnzygnostHBsAg 6.0 Siemens 201
8 
Enzygnost HIV Integral 4 Siemens EIAgen HCV Ab V4   Adaltis Enzygnost HBs Ag 6.0 Siemens 
  
201
7 HIV Ag-Ab  Ultra Biorad Monolisa Anti-HCV Plus v3 
Biorad 
EIAgen Detect HIV4  Total Screening 
Adaltis 




Enzygnost HIV Integral 4 Siemens Enzygnost Anti HCV 4 
Siemens 
EIAgen Detect HIV4  Total Screening 
Adaltis 
EIAgen HCV Ab V4   Adaltis EnzygnostHBsAg 6.0 Siemens 201
5 Enzygnost Anti HCV 4 
Siemens 
Murex HBsAg Version 3.0 
Diasorin 
  HCV Ultra Biomedical 
EIAgen Detect HIV4  Total Screening 
Adaltis 
HCV Ultra Biomedical EnzygnostHBsAg 6.0 Siemens 201
4 
HIV Ag-AbBiomerieux Innotest HCV Ab IV Murex HBsAg Version 3.0 
Diasorin 
  
Murex HIV Ag-Ab Murex Anti HCV Antibody V4 
HIV Ag-AbBiomerieux HCV Ultra Biomedical EnzygnostHBsAg 6.0 Siemens 201
3   HBsAg Ultra Biorad 
HIV Ag-AbBiomerieux HCV Ultra Biomedical EnzygnostHBsAg 6.0 Siemens 201
2     HBsAg Ultra Biorad 
HIV Ag-AbBiorad- HCV  Ab Ultra Biomedical EnzygnostHBsAg 6.0 Siemens 201
1 HIV Ag-AbBiomerieux   HBs Ag -Dade Behring 
HIV Ag-AbBiorad- HCV  Ab Ultra Biomedical HBs Ag -Dade Behring 
  
201
0 HIV Ag-AbBiomerieux HCV Ab Ortho 
HIV Ag-AbBiorad- HCV Ab Ortho HBs Ag -Dade Behring 
  
200
9 HIV Ag-AbBiomerieux   
HIV Ag-AbBiorad- HCV  Ab Ultra Biomedical HBs Ag -Dade Behring 
  
200
8 HIV Ag-AbBiomerieux HCV Ab Ortho 
HIV Ag-AbBiomerieux HCV  Ab Ultra Biomedical HBs Ag -Dade Behring 200
7 
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Table 3: The kits used in donor screening (Confirmatory), 2006-2018 
 
HIV Western Blot HCV RIBA HBs Ag Confirmatory test year 
HIV Blot MP Diagnostic HCV Blot  Riba MP diagnostic Anti HBc Monoclonal 
SimenseEnzygost 
2018 
Inno-LIA HIV I-II Score Fujirebio Inno-LIA HCV Score Fujirebio Anti HbsAg Confirmatory 
SimenseEnzygost 
HIV Blot MP Diagnostic HCV Blot  Riba MP diagnostic Anti HBc Monoclonal 
SimenseEnzygost 
2017 
Inno-LIA HIV I-II Score Fujirebio Inno-LIA HCV Score Fujirebio Anti HbsAg Confirmatory 
SimenseEnzygost 
HIV Blot MP Diagnostic HCV Blot  Riba MP diagnostic Anti HBc Monoclonal 
SimenseEnzygost 
2016 
Inno-LIA HIV I-II Score Fujirebio Inno-LIA HCV Score Fujirebio 
  
HBcSimenseEnzygnost 
  Inno-LIA HIV I-II Score Innogenetics 
HIV Blot MP Diagnostic HCV Blot  Riba MP diagnostic Murex Hbs Ag 
Confirmatory 
2015 
Murex HBc Total 
HBcSimenseEnzygnost 
HIV Blot MP Diagnostic HCV Blot  Riba MP diagnostic Murex Hbs Ag 
Confirmatory 
2014 
Inno-LIA HCV Score Fujirebio 
  
Murex HBc Total 
HBcSimenseEnzygnost 
HIV Blot MP Diagnostic HCV Blot  Riba MP diagnostic Anti HbsAg Confirmatory 
SimenseEnzygost 
2013 
Inno-LIA HIV I-II Score Innogenetics HBcSimenseEnzygnost 
HIV Blot MP Diagnostic HCV Blot  Riba MP diagnostic  HBcSimenseEnzygnost 2012 
Inno-LIA HIV I-II Score Innogenetics  
HIV Blot MP Inogenetic 
HIV Blot MP Inogenetic 
  
HCV Blot  Riba MP diagnostic Anti HBc PLUS Biorad 2011 
Inno-LIA HCV Score 
INNOGENETICS 
HBcSimenseEnzygnost 
HIV Blot MP Diagnostic 
  
HCV Blot  Riba MP diagnostic Anti HBc PLUS Biorad 2010 
Inno-LIA HCV Score 
INNOGENETICS 
  
HIV Blot MP Diagnostic HCV Blot  Riba MP diagnostic Anti HbsAg Confirmatory 
SimenseEnzygost 
2009 




HIV Blot MP Diagnostic HCV Blot  Riba MP diagnostic Anti HbsAg Confirmatory 
test   Dade Behring 
2008 




HIV Blot MP Diagnostic HCV Blot  Riba MP diagnostic Anti HbsAg Confirmatory 
test   Dade Behring 
2007 




HIV Blot MP Diagnostic 
  
HCV Blot  Riba MP diagnostic Anti HbsAg Confirmatory 
test   Dade Behring 
2006 
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Figure 1: Prevalence and trend of the initial, double check and confirmatory test of HBsAg infection among 
blood donors of Fars province, Iran, between 2006 to 2018 
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Figure 2: Prevalence and trend of the initial, double check and confirmatory test of HCV infection among 
blood donors of Fars province, Iran, from 2006 to 2018 
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Figure 3: Prevalence and trend of the initial, double check, and confirmatory test of HIV infection among 




Although blood transfusion is an integral part of 
medical therapy which can save millions of lives 
worldwide each year, it has a life-threatening 
hazard, too. Thus, proper selection of donors and 
sensitive screening  tests of all donated blood is 
essential to decrease  this risk to the minimum (10).  
Providing a safe and sufficient blood supply is one 
of the most important aims of any blood 
transfusion organization. For preventing 
transmission of viral infections, strict screening of 
all blood donations is necessary. In Iran, 
serological screening of all donated blood is 
obligatory for HBV, HCV, and HIV(11). 
Monitoring the trend of viral infections in the blood 
donor population over time  reveals  the efficacy of 
safety measures that were implanted by blood 
transfusion centers (12). Thus, the current study 
was conducted to find out the prevalence and trend 
of HBV, HCV, and HIV infections in all blood 
donations of Fars province from 2006 to 2018.  Our 
findings demonstrated a very low prevalence of 
TTIs among blood donors. The overall prevalence 
of TTIs among blood donors of Fars province was 
0.229% (n=4479) that was lower than the donors of 
Tehran province during 2005 to 2011 with the 
prevalence of 0.506% (13), and donors of Kerman 
province in 2009-2013 with the prevalence of 
0.316% (14). However, it was higher than 
Kohgiluyeh and Boyer-Ahmad province donors in 
2005-2014 with a prevalence of 0.204% (15). In 
the present study, the seroprevalences of HBV was 
0.137 % which is lower than the previous study 
conducted by Kasraian et al. in Fars province 
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between 2002 and 2005, which shows the 
effectiveness of the safety measures which were 
established  over time (16). Also, the prevalence of 
HBV in our study was lower than other studies 
reporting from different regions of Iran, such as 
Bushehr province from 2004 to 2014 with a 
prevalence of 0.15 (17), Tehran’s Blood 
Transfusion Center from 2005 to 2011 with a 
prevalence of 0.38%(13), and Tehran Blood 
Transfusion Center from 2003 to 2005 with a 
prevalence of 0.6%(18).  Other previous studies 
have also shown that the prevalence of HBV 
among blood donors in Fars province was very 
low; for example, a study that evaluated the 
prevalence of hepatitis B virus infection among 
blood donors of Fars province between 1998-2007 
showed the lowest prevalence of HBV among 
blood donors (19). This difference in the 
prevalence of HBV infection may be due to the 
differences in social behaviors, culture, lifestyle, 
socioeconomic status, the geographical distribution 
of the infection, and the level of awareness in 
different regions of our country. The prevalence of 
HBV in the present study was also lower than 
many countries such as Eastern Turkey (2.55%) 
(20), Pakistan (1.46%-2.99%) (21), India (1.96%) 
(22), Mali (13.9%) (23), China (0.87%) (24), and 
Mongolia (8.1%) (25). However, it was higher than 
other studies from Italy (0.0069%) (26), and 
Canada (0.007%-0.06%) (27).  
Furthermore, the present study showed that the 
prevalence of HBV amongst blood donors had a 
descending trend in this period, and significantly 
decreasing from 0.36% in 2006 to 0.024% in 2018. 
Such a decline may be due to improvement in 
donor recruitment, strict donor selection criteria 
during the pre-donation examination, and use of 
blood transfusion databases (19). Also, the 
prevalence of HBV infection   decreased 
dramatically in the Iranian population during the 
last decade. Improvement of the people’s 
knowledge about HBV risk factors, preventive 
measures, national vaccination program since 1993 
for all neonates, and vaccination of teenagers and 
high-risk groups can be the cause of this reduction 
(28). 
Our findings also indicated that HBV was 
more prevalent among the age range of 26-50 
years. This is in agreement with other studies, 
which have shown a remarkable association 
between higher HBV prevalence and older ages 
(24, 27, 29). This is due to engagement in high-risk 
behaviors over time and increasing exposure to 
HBV with age. 
The results of our study indicated that the 
overall seroprevalences of HCV was 0.087% 
between blood donors of Fars province which was 
lower than other studies conducted on Iranian 
blood donors such as 0.1% in Bushehr Province 
between 2004-2014(17), 0.13% in Iranian blood 
donors during 2004-2007 (12), 0.1% in Iranian 
blood donors from 2003 to 2005 (18), and 0.11% in 
blood donors of Tehran province from 2005-
2011(13). Different results on the prevalence of 
HCV infection among the Iranian blood donors 
may be due to the study periods, the sample size, 
the geographical regions, risk factors, and the 
sensitivity of HCV kits which were used (30). In 
comparison with countries in this geographical 
region, we have the lowest prevalence of HCV 
infection. The HCV prevalence in the present study 
is lower compared to many countries such as 
Pakistan (3.01%-4.99%) (21), Eastern Turkey ( 
0.17%) (20), Mali (3.3%) (23), China (0.86%) (24), 
and Kurdistan Region of Iraq (0.2%) (31), while 
the prevalence was higher than Australia (0.01%) 
(32), and Italy (0.0016%) (26). The wide variation 
of HCV seroprevalence in different parts of the 
world may be due to the population risks, health 
status, public awareness, use of different 
generations of ELISA test kits, the criteria of 
positivity, types of donors, quality of donor 
screening, and selection procedure in those 
regions(33).  
The highest HCV seroprevalence was 
observed among donors aged 26 to 35 years. The 
late positivity of anti-HCV may be due to exposure 
to its risk factors at an older age (34). Also, the 
results of this study indicated that the prevalence of 
HCV infection among blood donors in Fars 
province had a significant and impressive decline 
from 0.186% in 2006 to 0.0228% in 2018. The 
reasons for this decline were the implementation of 
more restrictive guidelines on physical examination 
before donation and the application of more 
sensitive HCV test kits for screening the blood by 
           Ethiop J Health Sci.                               Vol. 30,  No. 3                            May 2020 
 
 




Iran Blood Transfusion Centers (35). Furthermore, 
the public has become more aware of the routes of 
transmission of HCV infection in recent years. 
In the present study, the prevalence of HIV 
infection among blood donors was 0.0047%, which 
was lower than a study conducted on Iranian blood 
donors, such as 0.0053% in Tehran Province 
between 2005-2011 (13). However, it was higher 
than Kohgiluyeh and Boyer-Ahmad province with 
a prevalence of 0.0016% (15).  
Moreover, the prevalence of HIV is low 
compared to other parts of the world such as 
Eastern Turkey with 0.036% (20), Mangalore with 
0.1% (36), Eastern Ethiopia with 0.1 % (37), China 
with 0.31% (24), and Mali with 2.6% (23), but it 
was higher than the results reported from Australia 
(0.0003%) (32), Italy (0.00019%) (26), and 
Mongolia (0%) (25). 
Also, evaluating the prevalence of HIV 
infection among the blood donors showed a 
fluctuating and descending trend in this period 
from 0.0072% in 2006 to 0% in 2018. The 
government of Iran is committed to the provision 
of universal access to HIV prevention (free 
condom, education, HIV testing), and antiviral 
therapy services for all at-risk or affected 
populations as outlined in the 4th National AIDS 
Strategic Plan 2015–19 (6). These health policies 
and interventions led to the reduction of main 
blood-borne infections in Iran (38). 
The present study showed a higher prevalence 
of HBV, HCV, and HIV infections among first-
time donors compared to regular and repeat donors. 
These findings are consistent with those of other 
studies showing that the prevalence of viral 
infections was higher among first-time donors(39). 
The reason may be the denial of high-risk behavior 
at pre-donation screening or the donation of blood 
for HIV check-up. The lower prevalence of TTIs in 
repeat and regular blood donors may be due to the 
acquisition of information about the importance of 
safe blood in the previous donation, having a 
negative test in pervious donations and the lower 
probability of engagement in high-risk behavior 
(16). 
In our study, the seroprevalence of TTIs was 
lower among female donors compared to male 
ones. This finding is in the same line with previous 
studies reported from other areas of the world (12, 
37, 40). It may be due to a low number of females 
donating blood; therefore, fewer females are 
screened compared to males. Moreover, the lower 
contribution of women in social activities and high-
risk behaviors such as multiple sex relationships 
and intravenous drug use have a role in these 
gender differences (17, 37). 
Our findings revealed that the prevalence of 
TTIs was higher in married donors. It may be due 
to family problems and sexual reasons reported in 
other studies (13). 
Also, our findings indicated that the 
prevalence of HBV was significantly higher than 
that of HCV and HIV. Similar findings have also 
been reported from previous studies (12, 18). It 
may be due to more contagiousness of HBV risky 
sexual activities compared to HCV and HIV. 
However, HCV was transmitted mainly through 
transfusion of blood or blood products, intravenous 
drug abuse, and needle sharing(38, 40). Our study 
also demonstrated that despite an increase in the 
total blood donation from 2006 to 2018, the 
seroprevalence of HBV, HCV, and HIV has 
declined in blood donors. The implementation of 
some procedures in the Iran Blood Transfusion 
Organization might have led to the reduction of the 
TTIs in blood units. One of these procedures was 
implementing confidential unit exclusion (CUE) 
since 2002 for the identification and elimination of 
high-risk donors. Other safety measures were; data 
registry of all blood donors by computerized 
software and uniform donor deferral criteria, which 
has been implemented since 1997. Also, validating 
all procedures across the country and screening of 
first-time volunteer donors in 2017 and 2018 have 
had an important role in reduction of TTIs over 
time (17, 19). Also, in the last decade, educational 
efforts of IBTO to increase the public’s knowledge 
on TTIs and routes of transmission of TTIs have 
had a considerable role in reducing these infections 
in the donor population (19, 30). 
The results of the present study showed that 
the overall prevalence of TTIs among blood donors 
of Fars Province was low and has been steadily 
reduced over time. It reveals that donor screening 
and selecting policy established by Fars blood 
transfusion centers have been effective in recent 
years. 
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